Sharemaestro company-news research for Eli Lilly and Company (LLY), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
BUE
Argentina
Provisional evidence
Company news sentiment
Latest LLY news and sentiment
Eli Lilly and Company
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
33 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone60/100
→
Published 30-day score52/100
Latest source headline
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
finance.yahoo.com · 30 Sep 2026 22:00
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
33 current stories are mapped specifically to LLY.
What limits the score
Only 1 publisher currently contribute to the measured read.
The stories agree, but freshness-weighted evidence is only 0.160.
Confidence is 22/100, below the threshold for a firm score.
52/100
News scoreEarly balanced news score
22/100
Confidencethin evidence
78%/100
Company news33 company stories
95/100
Story agreement5/100 difference
News history
Daily score and story count over 30 days
02 Sep17 Sep01 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence3
0.16 after freshness weightingSource breadth20
1 independent publishersCompany relevance78
share tied directly to this companyFreshness61
recency-weighted evidenceAgreement95
how closely stories agreePublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks15 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
03 Apr30 Jun25 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
25 Sep 202655ARS 34300.0+4.1%
18 Sep 202657ARS 32940.0+3.3%
11 Sep 202653ARS 31880.0-1.8%
04 Sep 202653ARS 32480.0-2.9%
28 Aug 202652ARS 33440.0-6.4%
21 Aug 202658ARS 35740.0+7.6%
14 Aug 202662ARS 33220.0-0.6%
07 Aug 202664ARS 33414.458812+3.5%
Provisional evidence
News subjects
What is shaping the score
Market update5122 stories · 67%
Earnings505 stories · 15%
Deals and strategy523 stories · 9%
Regulatory and legal562 stories · 6%
Guidance681 stories · 3%
Source mix
Where the evidence comes from
finance.yahoo.com5333 stories · 100%
Recurring subjects
Subjects appearing most often
Pharma17Earnings12Fda Approval8Diabetes8Clinical Trials8Obesity7Earnings Growth7Biotech6Price Target4Healthcare4
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
07 Aug50 neutral01 Oct 03:56
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 01 Oct 03:56 | 50 | +0 | 34/100 (0) | 81 (-1) | Provisional |
| 30 Sep 23:59 | 50 | -2 | 34/100 (+1) | 82 (-7) | Provisional |
| 29 Sep 23:59 | 52 | -2 | 33/100 (+4) | 89 (+1) | Provisional |
| 28 Sep 23:59 | 54 | -1 | 29/100 (-3) | 88 (-5) | Provisional |
| 26 Sep 23:59 | 55 | +0 | 32/100 (-2) | 93 (-1) | Provisional |
| 25 Sep 23:59 | 55 | +0 | 34/100 (-3) | 94 (-4) | Provisional |
| 24 Sep 23:59 | 55 | +0 | 37/100 (+1) | 98 (0) | Provisional |
| 23 Sep 23:59 | 55 | +0 | 36/100 (0) | 98 (-4) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 33 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Regulatory and legal1 story
0.0%45.5%
Guidance1 story
0.0%32.2%
Deals and strategy2 stories
0.0%20.3%
Earnings1 story
0.0%1.4%
Market update2 stories
0.0%0.5%
Each side uses the same scale: 0–45.5% of the retained directional evidence.
Where the influence comes from
100.0%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the primary objective for non-inferiority compared to insulin glargine In pre-planned analyses, Foundayo showed a 53% lower risk of cardiovascular death and a 57% lowe…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the primary objective for non-inferiority compared to insulin glargine In pre-planned analyses, Foundayo showed a 53% lower risk of cardiovascular death and a 57% lower risk of all-cause death vs. insulin glargine, suggesting the potential for more comprehensive health benefits INDIANAPOLIS, Sept. 30, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced detailed results from the Phase 3 ACHIEVE-4 trial evaluating the e
- Published
- 30 Sep 2026 22:00
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 0.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Cardiovascular HealthClinical TrialsObesityPharmaType 2 Diabetes
—Unscored
Participants taking EloraTZP lost up to an average of 54.1 lbs (23.3%) compared to 34.4 lbs (14.8%) with tirzepatide 15 mg Participants taking EloraTZP lowered their A1C by up to an average of 2.9% compared to 2.4% with tirzepatide 15 mg Based on results of this 48-week Phase 2b study, Li…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Participants taking EloraTZP lost up to an average of 54.1 lbs (23.3%) compared to 34.4 lbs (14.8%) with tirzepatide 15 mg Participants taking EloraTZP lowered their A1C by up to an average of 2.9% compared to 2.4% with tirzepatide 15 mg Based on results of this 48-week Phase 2b study, Lilly will initiate Phase 3 trials of EloraTZP in Q4 2026 INDIANAPOLIS, Sept. 30, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive results from a Phase 2b trial evaluating the safety and efficacy of EloraTZP, an inve
- Published
- 30 Sep 2026 14:15
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 0.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Clinical TrialsObesityPharmaRegulationType 2 Diabetes
—Unscored
EBGLYSS monotherapy met its primary endpoint with more than half of patients achieving clear or almost clear skin on their hands and feet (HF-IGA 0/1) by Week 16, with significant skin clearance as early as one month EBGLYSS delivered significant itch and pain relief, with significant itc…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
EBGLYSS monotherapy met its primary endpoint with more than half of patients achieving clear or almost clear skin on their hands and feet (HF-IGA 0/1) by Week 16, with significant skin clearance as early as one month EBGLYSS delivered significant itch and pain relief, with significant itch improvements as early as two weeks in the Phase 3b ADtouch study In first-of-its-kind patient satisfaction data, nearly eight out of 10 patients treated with EBGLYSS reported being satisfied or very satisfied with hand clearance at Week 16 INDIANAPOLIS, Sept. 30, 2026 /PRNewswire/ -- Eli Lilly and Company (N
- Published
- 30 Sep 2026 12:03
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 0.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
BiotechClinical TrialsFda ApprovalPharma
—Unscored
Market updateNot used in direction
Eli Lilly Shares Rise After Foundayo Shows More Weight Loss
This article first appeared on GuruFocus. Eli Lilly (LLY) edged 1% higher in morning Tuesday trading after new data pointed to greater weight and blood-sugar reductions from its oral Foundayo treatment than oral semaglutide at higher doses. The analysis examined 17.2 mg of Foundayo, or or…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article first appeared on GuruFocus. Eli Lilly (LLY) edged 1% higher in morning Tuesday trading after new data pointed to greater weight and blood-sugar reductions from its oral Foundayo treatment than oral semaglutide at higher doses. The analysis examined 17.2 mg of Foundayo, or orforglipron, in adults with type 2 diabetes. At week 52, patients receiving the Lilly drug recorded 1.5% more body-weight reduction than those taking 25 mg of oral semaglutide. Warning! GuruFocus has detected 2 Warning Sign with MDB. Is LLY fairly valued? Test your thesis with our free DCF calculator.LLY GF Val
- Published
- 29 Sep 2026 18:23
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 1.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Clinical TrialsDiabetesPharma
—Unscored
In this new analysis, Zepbound 15 mg showed 4.5% greater weight loss than Wegovy HD in adults with obesity Participants receiving Zepbound 15 mg had more than three times the odds of achieving at least 20% body-weight reduction compared with Wegovy HD INDIANAPOLIS, Sept. 29, 2026 /PRNewsw…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
In this new analysis, Zepbound 15 mg showed 4.5% greater weight loss than Wegovy HD in adults with obesity Participants receiving Zepbound 15 mg had more than three times the odds of achieving at least 20% body-weight reduction compared with Wegovy HD INDIANAPOLIS, Sept. 29, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Foundayo (orforglipron), today announced results from a new analysis showing that Zepbound (tirzepatide) 10 mg and 15 mg, a dual GIP and GLP-1 receptor agonist, delivered greater weight loss than Wegovy HD (semaglutide injection 7.2 mg) in adults with obe
- Published
- 29 Sep 2026 11:00
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 1.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Clinical TrialsFda ApprovalObesityPharma
—Unscored
Deals and strategyNot used in direction
What Could Eli Lilly (LLY) New Cancer Win And Deal Shift Mean?
Eli Lilly (NYSE:LLY) received FDA Breakthrough Therapy designation for its next-generation KRAS G12C inhibitor olomorasib in advanced pancreatic cancer. The pharmaceutical group launched a global Change the Course program aimed at broadening access to its diabetes and obesity treatments i…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Eli Lilly (NYSE:LLY) received FDA Breakthrough Therapy designation for its next-generation KRAS G12C inhibitor olomorasib in advanced pancreatic cancer. The pharmaceutical group launched a global Change the Course program aimed at broadening access to its diabetes and obesity treatments in low and middle income countries. CEO Dave Ricks signaled a shift toward larger acquisitions in new therapeutic areas that extend beyond the firm's current obesity focus. The Breakthrough Therapy status for olomorasib, together with the Change the Course rollout, sits within wider shifts our research has iden
- Published
- 29 Sep 2026 07:08
- News subject
- Deals and strategy
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 1.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
AcquisitionsFda ApprovalOncologyPharma
—Unscored
Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks These additional analyses build on findings of the ACHIEVE-3 head-to-head study, where Foundayo 9 mg and 17.2 mg delivered greater A1C and weight reductions…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks These additional analyses build on findings of the ACHIEVE-3 head-to-head study, where Foundayo 9 mg and 17.2 mg delivered greater A1C and weight reductions than oral semaglutide 14 mg INDIANAPOLIS, Sept. 29, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from a new analysis showing that Foundayo (orforglipron) 17.2 mg was associated with significantly greater weight loss and better blood sugar
- Published
- 29 Sep 2026 07:00
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 1.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Clinical TrialsDiabetesFda Approval
—Unscored
Market updateNot used in direction
Eli Lilly and Company (LLY) is Expanding Beyond its Biggest Growth Drivers. Can it Sustain the Momentum?
On September 25, Eli Lilly and Company (NYSE:LLY) announced that the U.S. FDA approved Olumiant (baricitinib), a once-daily pill, for pediatric patients 12 years of age and older with severe alopecia areata (AA). The decision expands Olumiant's label beyond established adult indications i…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
On September 25, Eli Lilly and Company (NYSE:LLY) announced that the U.S. FDA approved Olumiant (baricitinib), a once-daily pill, for pediatric patients 12 years of age and older with severe alopecia areata (AA). The decision expands Olumiant's label beyond established adult indications in moderately to severely active rheumatoid arthritis and severe AA, enlarging its addressable market within immunology. While this broadens commercial reach for an existing asset, investors must weigh the incremental growth potential against broader operational and competitive pressures. You May Also Want To R
- Published
- 28 Sep 2026 04:11
- News subject
- Market update
- Why this score
- Contract or approval won
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 3.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Fda ApprovalFinancial ResultsImmunologyLabel ExpansionPharmaRevenue Guidance
—Unscored
Market updateNot used in direction
Eli Lilly (LLY) vs. Novo Nordisk (NVO): Has the GLP-1 Race Changed the Moat?
Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) were once viewed as the two big winners of the GLP-1 boom. However, the market's view of the two companies has changed sharply. Since mid-2024, Novo's stock has fallen roughly 74%, while Lilly's has gained about 35%. That di…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) were once viewed as the two big winners of the GLP-1 boom. However, the market's view of the two companies has changed sharply. Since mid-2024, Novo's stock has fallen roughly 74%, while Lilly's has gained about 35%. That difference is also reflected in their valuations, with Eli Lilly trading at about 24.4x forward earnings compared with just 11.8x for its Danish competitor. DON'T MISS: A Failed Cholesterol Drug Raises the Stakes for Amgen (AMGN) and Eli Lilly (LLY) Too The difference doesn't appear to be just about valuation, t
- Published
- 26 Sep 2026 05:16
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 5.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
CompetitionEarningsEarnings GrowthObesity DrugsPharmaValuation
57/100 tone
Regulatory and legal
Eli Lilly (LLY) Wins Two FDA Approvals And A $3.35 Billion Drug Alliance
Eli Lilly (NYSE:LLY) received FDA approval for Olumiant to treat pediatric patients with severe alopecia areata. The FDA also cleared once weekly insulin Onswik for adults with type 2 diabetes, adding a new dosing option. Eli Lilly agreed a global drug discovery alliance with InnoCare Pha…
45.5% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Eli Lilly (NYSE:LLY) received FDA approval for Olumiant to treat pediatric patients with severe alopecia areata. The FDA also cleared once weekly insulin Onswik for adults with type 2 diabetes, adding a new dosing option. Eli Lilly agreed a global drug discovery alliance with InnoCare Pharma valued at up to US$3.35b in research and licensing commitments. These combined FDA approvals and the US$3.35b InnoCare alliance deserve weighing against the rest of our Eli Lilly analysis. We have also spotted 1 warning sign worth knowing about at Eli Lilly. This mix of new treatments and research partners
- Published
- 26 Sep 2026 04:16
- News subject
- Regulatory and legal
- Why this score
- Fda Approval
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 43/100
- 30-day weight
- 45.5% of directional evidence · 5.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
DiabetesFda ApprovalImmunologyPartnershipsPharma
—Unscored
Market updateNot used in direction
Eli Lilly (LLY) Stock Is Up, What You Need To Know
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after The U.S. Food and Drug Administration approved Eli Lilly's once-weekly basal insulin, Onswik, for adults with type 2 diabetes, giving patients an alternative to daily lon…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after The U.S. Food and Drug Administration approved Eli Lilly's once-weekly basal insulin, Onswik, for adults with type 2 diabetes, giving patients an alternative to daily long-acting insulin shots. According to Reuters, Lilly said Onswik — chemically known as insulin efsitora alfa-gobe — is intended to be used with diet and exercise to help control high blood sugar and could cut the number of injections by more than 300 per year versus once-daily basal insulin. The company said th
- Published
- 24 Sep 2026 21:52
- News subject
- Market update
- Why this score
- Large positive market reaction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Consensus EstimateDiabetesEarningsEarnings EstimateEarnings GrowthEarnings Per Share
—Unscored
Market updateNot used in direction
Should Eli Lilly (LLY) Investors Watch Its $6.5 Billion Houston GLP 1 Buildout?
Eli Lilly (NYSE: LLY) has started construction on a US$6.5b manufacturing facility in Houston to produce its oral GLP-1 drug Foundayo. The new site is focused on supplying Foundayo for obesity treatment as demand for oral GLP-1 therapies grows in the US and abroad. The project includes pa…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Eli Lilly (NYSE: LLY) has started construction on a US$6.5b manufacturing facility in Houston to produce its oral GLP-1 drug Foundayo. The new site is focused on supplying Foundayo for obesity treatment as demand for oral GLP-1 therapies grows in the US and abroad. The project includes partnerships for local workforce training in Houston to support specialized pharmaceutical manufacturing roles. This large Houston buildout for Foundayo is an important piece to weigh alongside the rest of our Eli Lilly view. Take a look at 1 warning sign we have identified for Eli Lilly. Eli Lilly is far from t
- Published
- 22 Sep 2026 21:15
- News subject
- Market update
- Why this score
- Operating growth
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
DiabetesExpansionManufacturingObesity TreatmentPharma
—Unscored
Market updateNot used in direction
Eli Lilly CEO Delivers Urgent Message on the Company's Next Big Weight-Loss Pill
This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) is expanding manufacturing capacity for its new oral obesity treatment as Chief Executive David Ricks said the drug is gaining ground among patients starting GLP-1 pills. Ricks told CNBC that Foundayo accounts for roughly one-…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) is expanding manufacturing capacity for its new oral obesity treatment as Chief Executive David Ricks said the drug is gaining ground among patients starting GLP-1 pills. Ricks told CNBC that Foundayo accounts for roughly one-third of new oral GLP-1 prescriptions, with its share continuing to rise. The company also expects to introduce the treatment in additional international markets over the coming months. Is LLY fairly valued? Test your thesis with our free DCF calculator.LLY GF Value chart The comments came as Lilly broke groun
- Published
- 22 Sep 2026 12:49
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
ExpansionManufacturingObesity TreatmentsPharma
—Unscored
Market updateNot used in direction
Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020
New facility will manufacture active pharmaceutical ingredients for medicines like Foundayo (orforglipron), strengthening domestic supply chain Site will employ more than 600 people in high-wage jobs $12.5 million in support to build talent pipeline, workforce training center with San Jac…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
New facility will manufacture active pharmaceutical ingredients for medicines like Foundayo (orforglipron), strengthening domestic supply chain Site will employ more than 600 people in high-wage jobs $12.5 million in support to build talent pipeline, workforce training center with San Jacinto College HOUSTON, Sept. 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) broke ground today in Houston, Texas, one of ten U.S. manufacturing sites — and fifth location to produce domestic active pharmaceutical ingredients (API) — announced since 2020. As part of the company's $50 billion push to
- Published
- 21 Sep 2026 21:40
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
BiotechManufacturingObesity TreatmentPharmaceuticals
—Unscored
Regulatory and legalNot used in direction
Eli Lilly (LLY) Could Be 22% Undervalued On New Breast Cancer Approval
Eli Lilly (LLY) is back in focus after the U.S. Food and Drug Administration granted full approval for Inluriyo, used with Verzenio in certain ESR1 mutated metastatic breast cancer patients. Eli Lilly's share price has eased over the past month, with a 30-day share price return of 8.16% i…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Eli Lilly (LLY) is back in focus after the U.S. Food and Drug Administration granted full approval for Inluriyo, used with Verzenio in certain ESR1 mutated metastatic breast cancer patients. Eli Lilly's share price has eased over the past month, with a 30-day share price return of 8.16% in the red. However, the 1-year total shareholder return of 53.68% and roughly 4x gain over five years point to momentum that remains firmly intact. Compare Eli Lilly's oncology and obesity story with other potential breakouts by scanning our handpicked list of 37 healthcare AI stocks that are using data and AI
- Published
- 21 Sep 2026 17:11
- News subject
- Regulatory and legal
- Why this score
- Positive valuation view
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Balance SheetFda ApprovalObesityOncologyPharmaShare Price
—Unscored
Market updateNot used in direction
Eli Lilly (LLY) Stock Fair Value Edges Higher As Analysts Back GLP 1 Growth
Eli Lilly's updated fair value estimate has shifted from US$1,297.31 to US$1,325.39, adding a fresh data point to an already closely watched price target range. This move sits alongside analyst price targets that often sit above US$900, with a cluster between US$1,300 and US$1,600, as res…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Eli Lilly's updated fair value estimate has shifted from US$1,297.31 to US$1,325.39, adding a fresh data point to an already closely watched price target range. This move sits alongside analyst price targets that often sit above US$900, with a cluster between US$1,300 and US$1,600, as research teams debate how much of the GLP-1 and obesity story is already reflected in the stock. As you read on, you will see how to track these evolving views and what they may mean for your own Eli Lilly research process. Stay updated as the Fair Value for Eli Lilly shifts by adding it to your watchlist or port
- Published
- 20 Sep 2026 04:18
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.0d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFda ApprovalHealthcarePharmaPrice Target
57/100 tone
Deals and strategy
What Does Eli Lilly (LLY) Gain From Its New Genetic Medicine Partnership?
Eli Lilly (NYSE:LLY) has entered an exclusive research collaboration with QurCan Therapeutics to develop genetic medicines for nervous system diseases. The agreement centers on QurCan's polymer lipid nanoparticle delivery platform for central and peripheral nervous system targets, with El…
15.7% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Eli Lilly (NYSE:LLY) has entered an exclusive research collaboration with QurCan Therapeutics to develop genetic medicines for nervous system diseases. The agreement centers on QurCan's polymer lipid nanoparticle delivery platform for central and peripheral nervous system targets, with Eli Lilly responsible for later development and commercialization. Lilly is also making a strategic investment in QurCan Therapeutics, tying capital directly to progress in genetic medicine delivery technology. This new Lilly and QurCan genetic medicine partnership sits against a wider backdrop that our research
- Published
- 18 Sep 2026 10:10
- News subject
- Deals and strategy
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 36/100
- 30-day weight
- 15.7% of directional evidence · 12.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
AI DiscoveryDrug DeliveryGenetic MedicineNeurodegenerative DiseasesPharmaceuticals
68/100 tone
On September 15, Berenberg upgraded its rating on Eli Lilly and Company (NYSE:LLY) from Hold to Buy and lifted its price target from $1,220 to $1,400. The research firm pointed to the company's strong returns on investment and its growth in the obesity treatment market. Berenberg said its…
32.2% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
On September 15, Berenberg upgraded its rating on Eli Lilly and Company (NYSE:LLY) from Hold to Buy and lifted its price target from $1,220 to $1,400. The research firm pointed to the company's strong returns on investment and its growth in the obesity treatment market. Berenberg said its 2026 return on research investment analysis confirms the company's track record of delivering best-in-class returns. The firm sees potential for about 25% upside for the stock and expects the company to exceed its fiscal 2026 guidance.Eli Lilly (LLY) Gets a Big Price Target Boost, Analysts See 20% Upside Eli
- Published
- 17 Sep 2026 15:51
- News subject
- Guidance
- Why this score
- Analyst upgrade
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 49/100
- 30-day weight
- 32.2% of directional evidence · 13.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
DiabetesObesity TreatmentPharmaceuticalsPrice TargetUpgrade Downgrade
66/100 tone
On August 31, 2026, Reuters reported on a new study finding that patients who stay on the lowest starter doses of GLP-1 weight-loss drugs still lose weight, though far less than at full recommended doses, and experience less nausea. Patients on Eli Lilly and Company (NYSE:LLY)'s low-dose …
0.5% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
On August 31, 2026, Reuters reported on a new study finding that patients who stay on the lowest starter doses of GLP-1 weight-loss drugs still lose weight, though far less than at full recommended doses, and experience less nausea. Patients on Eli Lilly and Company (NYSE:LLY)'s low-dose tirzepatide lost an average of 5.5% of their body weight over a year, versus 2.2% for Novo Nordisk A/S (NYSE:NVO)'s low-dose semaglutide, compared with 20.2% and 13.7% respectively at the higher, manufacturer-recommended doses seen in earlier trials. The low-dose tirzepatide group also showed higher rates of c
- Published
- 17 Sep 2026 15:46
- News subject
- Market update
- Why this score
- Loss narrowed
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 36/100
- 30-day weight
- 0.5% of directional evidence · 13.6d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
ObesityPharmaRevenue GrowthWeight Loss
—Unscored
Market updateNot used in direction
LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?
Eli Lilly and Company's LLY stock has declined around 7.2% in the past month after gaining sharply earlier in 2026 and trading near record levels. At around 26.3x forward earnings, LLY continues to command a premium valuation, making the stock more vulnerable to profit-taking and broader …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Eli Lilly and Company's LLY stock has declined around 7.2% in the past month after gaining sharply earlier in 2026 and trading near record levels. At around 26.3x forward earnings, LLY continues to command a premium valuation, making the stock more vulnerable to profit-taking and broader market volatility. Investors have also become more focused on competition in the fast-growing obesity-drug market, particularly in the oral GLP-1 segment, where Lilly's oral GLP-1 pill Foundayo is competing with Novo Nordisk's NVO Wegovy pill. Nevertheless, continued strength in Mounjaro, Zepbound and Foundayo
- Published
- 17 Sep 2026 15:08
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.6d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
DiabetesEarningsFourth QuarterGlp 1ObesityPharma
—Unscored
Market updateNot used in direction
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this drugmaker have returned -7.3%, compared to …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this drugmaker have returned -7.3%, compared to the Zacks S&P 500 composite's -2.4% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Lilly falls in, has lost 0.6%. The key question now is: What could be the stock's future direction? While media releases or rumors about a substantial change in a company's business prospects usu
- Published
- 16 Sep 2026 13:00
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Consensus EstimateEarningsEarnings EstimateEarnings GrowthForecastIntrinsic Value
—Unscored
Market updateNot used in direction
Eli Lilly (LLY) Stock Could Be A Bargain At This Price
Eli Lilly has turned into one of the market's biggest healthcare stories, with the share price at US$1,136.11 and a very large 5 year gain, so the obvious question for you is whether that move is backed up by the cash the business can generate. With so much of the current debate driven by…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Eli Lilly has turned into one of the market's biggest healthcare stories, with the share price at US$1,136.11 and a very large 5 year gain, so the obvious question for you is whether that move is backed up by the cash the business can generate. With so much of the current debate driven by excitement around obesity and diabetes treatments, the price now invites a closer look at what those therapies may mean for long term cash flows. The stock is up about 416.5% over 5 years, which puts a lot of weight on the idea that Lilly's future cash flows can justify a much higher valuation than in the pas
- Published
- 16 Sep 2026 12:13
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Cash FlowDiabetesEarningsFree Cash FlowFuture Cash FlowsHealthcare
—Unscored
Market updateNot used in direction
Circle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical Development
Financing led by The Column Group with participation from Nextech Invest, RA Capital Management, Euclidean Capital and a strategic investment from Eli Lilly and Company CID-165, a first-in-class oral macrocyclic cyclin D1 RxL inhibitor, is expected to enter clinical development in Q1 2027…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Financing led by The Column Group with participation from Nextech Invest, RA Capital Management, Euclidean Capital and a strategic investment from Eli Lilly and Company CID-165, a first-in-class oral macrocyclic cyclin D1 RxL inhibitor, is expected to enter clinical development in Q1 2027 for patients with ER+ breast cancer CID-165 has demonstrated robust anti-tumor activity in cyclin D1-driven preclinical cancer models, including in combination with CDK4/6-dual inhibitors, CDK4-selective inhibitors and endocrine therapies SOUTH SAN FRANCISCO, Calif., September 16, 2026--(BUSINESS WIRE)--Circl
- Published
- 16 Sep 2026 11:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechBreast CancerClinical TrialsFinancing
—Unscored
Market updateNot used in direction
3 Healthcare Stocks for 3 Stages of Life
Key Points Interested in Eli Lilly and Company? Here are five stocks we like better. The healthcare sector offers options for investors of every age, combining high-growth drugmakers, defensive operators, and reliable dividend payers. Eli Lilly suits younger investors with its obesity and…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Key Points Interested in Eli Lilly and Company? Here are five stocks we like better. The healthcare sector offers options for investors of every age, combining high-growth drugmakers, defensive operators, and reliable dividend payers. Eli Lilly suits younger investors with its obesity and diabetes drug pipeline driving growth, having gained nearly 34% since its April low. UnitedHealth Group fits middle-aged investors with a turnaround story and rising dividend, while Johnson & Johnson's Dividend King status appeals to older, income-focused investors. When it comes to investing, there is no one
- Published
- 15 Sep 2026 18:05
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.5d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
DividendsEarnings Per ShareGrowth RateGrowth StocksHealthcarePrice Target
—Unscored
Multi-program collaboration leveraging QurCan's TERP™ polymer-lipid nanoparticle delivery platform Lilly to make a strategic investment in QurCan TORONTO, September 15, 2026--(BUSINESS WIRE)--QurCan Therapeutics ("QurCan"), a biotechnology company pioneering non-viral, polymer-lipid nanop…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Multi-program collaboration leveraging QurCan's TERP™ polymer-lipid nanoparticle delivery platform Lilly to make a strategic investment in QurCan TORONTO, September 15, 2026--(BUSINESS WIRE)--QurCan Therapeutics ("QurCan"), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company ("Lilly") for the treatment of diseases of the central nervous system (CNS) and peripheral ner
- Published
- 15 Sep 2026 10:00
- News subject
- Market update
- Why this score
- Strategic partnership
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechCollaborationGenetic MedicineNeuroscience
—Unscored
Market updateNot used in direction
Lilly’s Obesity Access Push via Medicare Bridge Might Change The Case For Investing In Eli Lilly (LLY)
Eli Lilly and Company recently presented at Morgan Stanley's Global Healthcare Conference, where executive vice president Ilya Yuffa outlined efforts to expand access to its obesity medicines, including Zepbound and Foundayo, and highlighted broader international growth initiatives. This …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Eli Lilly and Company recently presented at Morgan Stanley's Global Healthcare Conference, where executive vice president Ilya Yuffa outlined efforts to expand access to its obesity medicines, including Zepbound and Foundayo, and highlighted broader international growth initiatives. This focus on widening obesity treatment access through consumer advertising, Medicare Bridge support, and global reach underlines how central these therapies have become to Lilly's long-term business mix. We'll now examine how Lilly's push to broaden access to obesity treatments, particularly via the Medicare Brid
- Published
- 15 Sep 2026 03:24
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.1d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsEarnings GrowthMedicareObesity TreatmentsPricing PressureRevenue Growth
—Unscored
Market updateNot used in direction
Why the Market Dipped But Eli Lilly (LLY) Gained Today
In the latest close session, Eli Lilly (LLY) was up +1.99% at $1,137.86. This move outpaced the S&P 500's daily loss of 0.48%. Meanwhile, the Dow experienced a drop of 0.29%, and the technology-dominated Nasdaq saw a decrease of 0.56%. Shares of the drugmaker have depreciated by 5.46% ove…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
In the latest close session, Eli Lilly (LLY) was up +1.99% at $1,137.86. This move outpaced the S&P 500's daily loss of 0.48%. Meanwhile, the Dow experienced a drop of 0.29%, and the technology-dominated Nasdaq saw a decrease of 0.56%. Shares of the drugmaker have depreciated by 5.46% over the course of the past month, underperforming the Medical sector's loss of 2.01%, and the S&P 500's loss of 0.82%. Investors will be eagerly watching for the performance of Eli Lilly in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on October 29, 2026. The company's up
- Published
- 14 Sep 2026 21:45
- News subject
- Market update
- Why this score
- Large negative market reaction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.3d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Analyst EstimatesConsensus EstimateEarningsEarnings GrowthEarnings ReportMedical
—Unscored
Market updateNot used in direction
Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer
During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cram…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond that, I've got a couple more running backs. Eli Lilly's become a great compounder thanks to its booming GLP-1 weight loss business. For an NFL comparison, we're going to have to stay in Indianapolis where Lilly's based, and give you Colts running back Jonathan Taylor, entering his seventh seaso
- Published
- 12 Sep 2026 11:35
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechEarningsHealthcarePharmaPrice Target
—Unscored
Market updateNot used in direction
Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks
On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I'll tell you… I think it's always good to…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I'll tell you… I think it's always good to look at Lilly as a stock that I think has a lot of things that are going well, but I want to wait. Well, actually, you know, tell you the truth… It's pulled back. I think you're fine, I think you're fine to add some. I'm going to okay that. And I understand JNJ's moved a great deal. It's been a great club hit
- Published
- 09 Sep 2026 19:12
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 21.4d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Balance SheetEarningsEarnings GrowthFinancial ResultsGrowthGrowth Rate
43/100 tone
Market update
Here's Why Eli Lilly (LLY) Fell More Than Broader Market
In the latest close session, Eli Lilly (LLY) was down 2.21% at $1,123.91. This change lagged the S&P 500's 0.58% loss on the day. At the same time, the Dow lost 1.18%, and the tech-heavy Nasdaq lost 0.32%. Shares of the drugmaker have depreciated by 6.7% over the course of the past month,…
<0.1% of directional evidence
Low story strength
Scoring detailsDirect company coverage
In the latest close session, Eli Lilly (LLY) was down 2.21% at $1,123.91. This change lagged the S&P 500's 0.58% loss on the day. At the same time, the Dow lost 1.18%, and the tech-heavy Nasdaq lost 0.32%. Shares of the drugmaker have depreciated by 6.7% over the course of the past month, underperforming the Medical sector's gain of 2.73%, and the S&P 500's loss of 0.36%. Analysts and investors alike will be keeping a close eye on the performance of Eli Lilly in its upcoming earnings disclosure. The company's earnings report is set to go public on October 29, 2026. It is anticipated that the c
- Published
- 08 Sep 2026 21:45
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 26/100
- 30-day weight
- <0.1% of directional evidence · 22.3d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Analyst EstimatesConsensus EstimateEarningsEarnings GrowthEarnings ReportEstimate Revisions
Earlier company news
LLY news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 75 older LLY headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to LLY, but the headline and available text are not mainly about Eli Lilly and Company. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of LLY sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.